

# VIRTUAL MEETING

## DIA-CoRE Singapore Annual Meeting 2020 -Driving Healthcare Innovation and Collaboration in Asia

Organised by DIA and CoRE

**New Dates: 6-7 July & 13-14 July, 2020**

**DIA**

**CoRE**  
Centre of Regulatory Excellence  
at Duke-NUS Medical School

### PROGRAMME CO-CHAIRS



**Dorothee GRIMALD**  
Director  
Global Regulatory Policy  
MSD Singapore



**James LEONG**  
Head of Pharmaceutical  
Regulatory Science  
Programme  
Centre of Regulatory  
Excellence (CoRE)  
Duke-NUS Medical School

### ADVISORY COMMITTEE



**Shun JIN**  
Head, Regulatory Affairs  
APMA  
Sandoz



**Kum Cheun WONG**  
Head Asia Pacific  
Regulatory & Development  
Policy, Novartis Asia Pacific  
Pharmaceuticals Pte Ltd



**Jing Ping YEO**  
Director, Research Integrity,  
Compliance and Ethics  
Singapore Health Services  
Ptd Ltd



**Fredrik Nyberg**  
Managing Director  
Asia Pacific  
MedTech Innovator



**Vicky HAN**  
Senior Director  
Policy Group Lead for Asia  
Pacific, Global Regulatory  
Affairs, Janssen Asia Pacific

### PROGRAMME COMMITTEE



**Audrey Ooi**  
Acting Head  
Business Development  
Clinical Research Malaysia



**Mei Ding**  
JAPAC Regional Lead,  
Regulatory Policy and  
Intelligence  
AbbVie Pte. Ltd



**Finny Liu**  
APAC Regional Regulatory  
Policy Lead  
PDR  
Roche, Singapore



**Thean Soo (TS) Lo**  
Regulatory Affairs  
Management Consultant



**Jack Wong**  
Founder  
Head of Regulatory Affairs  
International (RegASK)  
ARPA (Asia Regulatory  
Professionals Association)



**Yasha Huang**  
Regional Regulatory Affairs and  
Policy Lead  
Roche Diagnostics Asia Pacific

### MEETING MANAGER

**Kanchan PATEL**

Associate Director Operations  
DIA (India) Private Limited | cell: +91 90.2909.8844 | kanchan.patel@diaglobal.org

**Sherna WADIA**

Associate Director  
Centre of Regulatory Excellence | Phone: +65 66015147 | CoRE@duke-nus.edu.sg

In the current landscape of rapid advances in medical sciences and technology, many opportunities abound for improving the quality and delivery of healthcare. New technology, systems and concepts are constantly explored to bring better health outcomes for patients. Beyond innovations in health products, IT continue to advance the changes with increasing utility of data sciences and Artificial Intelligence in transforming healthcare management. Given the complex interactions among the stakeholders, it is vital to be well-informed of the significant progresses and collaboration with relevant stakeholders to fully harness the value of this exciting evolution in healthcare

### Program Highlights

- Innovations and new paradigms that redefined healthcare
- Data sciences for enhancing the quality of patient care in Asia
- Convergence and reliance pathways – fostering partnerships among stakeholders
- Townhall on ASEAN regulatory matters

### Who should attend?

- Industry professionals in Pharmaceuticals and Medical Technologies involved in Research & Development, Regulatory Affairs, Market Access and Medical Affairs
- Regulators and personnel from Health Authorities and Ministries
- Academia and Researchers

**REGISTRATION OPEN**

Session 1 – Connected Care with Innovation

Chair: **Dorothee GRIMALD**

Director Global Regulatory Policy  
MSD Singapore

Our panelists will discuss how health innovations and technologies impact the healthcare system and can deliver patient care outside the traditional medical setting

3.00pm **Welcome and Opening Remarks**

**Shun JIN**  
Head, Regulatory  
Affairs APMA  
Sandoz

**Dorothee GRIMALD**  
Director Global Regulatory Policy  
MSD Singapore

3.15pm **Have Healthcare Innovations Delivered Their Promises? A Review of Connected Care and Measures of Success**

- Overview of impact that innovation and technology have on healthcare
- Defining connected care from patient's perspective
- Practical goals to monitor progress in achieving connected care

**Keren Priyadarshini**  
Regional Business Lead  
Worldwide Health  
Microsoft Asia

3.45pm **How Technology Companies Are Redefining Connected Care**

- Journey of transformation into a pharma company
- Ideals of a connected care model and the challenges in implementation

**Fabio La Mola**  
Partner, Global Healthcare Co-Head, Asia-Pacific  
L.E.K. Consulting

4.15 pm Tea / Coffee Break

4.30 pm **Panel Discussion : Connected Care with Innovation**

Moderator

**Jing Ping YEO**

Director, Research Integrity, Compliance and Ethics  
Singapore Health Services Ptd. Ltd.

Panelists

**Keren Priyadarshini**  
Regional Business Lead  
Worldwide Health  
Microsoft Asia

**Fabio La Mola**  
Partner  
Global Healthcare Co-Head  
Asia-Pacific  
L.E.K. Consulting

**Daniel Ting**  
Assistant Professor  
Ophthalmology  
Duke-NUS Medical School

**Fredrik Nyberg**  
Managing Director  
Asia Pacific  
MedTech Innovator

5.15 pm **Networking & Exhibit Visit**

6.00 pm **Day End**

Session 2 – Innovations in Healthcare - Med Devices & Tech

Co-Chairs:

**Yasha HUANG**

Regulatory Affairs & Policy  
Roche Diagnostics Asia Pacific

**Jack WONG**

Founder  
Head of Regulatory Affairs International (RegASK)  
ARPA (Asia Regulatory Professionals Association)

This event showcases the latest trends and issues in medical technologies. The topics will look into products and processes that hold promises to impact and advance the quality of patient care.

---

9.00am **3D Printing for Personalised Medical Devices**

- Evolution of 3D printing technology in healthcare
- Challenges in bringing additive manufacturing into health product development space

**Marc Engelhardt**

Manger – Clinical Affairs  
Stryker, Germany

---

9.20am **Disruptive Technology - Innovating Clinical Trials**

- Advancement of wearables and patient technologies
- Progress in the utility of virtual clinical trials

**Ross Rothmeier**

Vice President -Technology  
Medidata, a Dassault Systèmes company

---

9.40am **Artificial Intelligence in Radiology : where we are in 2020**

- Understanding machine learning (ML) and deep learning (DL) as basis in AI
- Utility in progressing healthcare

**Thian Yee Liang**

Senior Consultant  
Department of Diagnostic Imaging  
National University Hospital

---

10.00am Break

---

10.20am **Digital therapeutics (DTx) as evidence-based therapeutic interventions driven by high quality software programs**

- Global responses to this new treatment domain
- Gaps and uncertainties for regulating digital therapies

**Sethurama Rama**

Director  
Medical Devices Branch, Medical Devices Cluster  
Health Products Regulation Group  
Health Sciences Authority

---

10.40am **Revolutions in the Regulation of Artificial Intelligence Development of AI regulations in APAC markets**

- Global benchmarking and gap assessment

**Nate Carrington**

Vice President - Quality and Regulatory  
Diagnostics Information Solutions  
Roche Diagnostics

---

11.00am **Panel discussion: Addressing Concerns in Digital Health**

- Progress in cybersecurity: Storage, transfer, and encryption of data
- Legal and ethics issues regarding patients, privacy and rights

**Moderator**

**Ross Rothmeier**

Vice President -Technology  
Medidata, a Dassault Systèmes company

**Panellists**

**SETHURAMAN Rama**

Director -Medical Devices Branch, Medical Devices Cluster  
Health Products Regulation Group  
Health Sciences Authority

**Snehal Patel**

CEO and co-founder  
My-doc and Galen Growth Asia

**Steven Bell**

Senior Vice-President  
Diagnostic Imaging and Digital Health Asia-Pacific  
Siemens Healthineers

**Thian Yee Liang**

Senior Consultant  
Department of Diagnostic Imaging  
National University Hospital

11.30am **Networking**

**Session 3 – Innovations in Healthcare - Pharma**

**Co-Chairs**

**James LEONG**

Head of Pharmaceutical  
Regulatory Science Programme  
Centre of Regulatory Excellence (CoRE)  
Duke-NUS Medical School

**Mei DING**

JAPAC Regional Lead  
Regulatory Policy and Intelligence  
AbbVie Pte. Ltd

This event showcases the latest trends and issues in pharmaceutical development and healthcare management. The topics will look into products and processes that hold promises to impact and advance the quality of patient care.

3.00pm **Personalised Healthcare – Pivotal Role for Next Generation Sequencing**

- Impact on healthcare management
- Potential barriers to implementation into clinical practice

**Devmanyu Singh**

Foundation Medicine Transformation Lead Pharma International  
Roche Singapore Pte Ltd

3.20pm **Gene and Cell Therapy in Asia: Where We Are Now and What is Next?**

- Progress in Asia for adapting to the changing landscape in advanced therapies
- Opportunities to enhance the environment

**Tan Wee Kiat**

Chief Operating Officer  
CytoMed

3.40pm **Practical Utility of Real World Data**

- Case studies in drug development and regulatory decision-making
- Advancing patient-centric care with RWE

**Chris Pashos**

Independent Consultant

---

4.00pm Break

---

4.20pm **Innovation in Pharmacovigilance**

---

- New approaches for optimising product life cycle management
- Platforms for multi-stakeholder involvement

**Jean-Christophe Delumeau**

Head of Pharmacovigilance Policy Strategy  
QPPV Office  
Bayer Pharma (Singapore)

---

4.50 pm **E-labelling as a Tool for Enhancing Patient Care**

---

- Utility and value of e-labelling in improving care management
- Global progress and impact measures

**Aimad Torqui**

Director  
Global Regulatory Policy  
MSD

---

5.15 pm **Panel Discussion : elabelling implementation**

---

**Moderator**

**Rie Matsui**

DIA Asia Labelling Community  
Pfizer

**Panelists**

**Po Wen Yang**

Section Chief  
Division of Medicinal Products  
Taiwan FDA

**Junko Sato**

Office Director  
Office of International Program  
PMDA

**Aimad Torqui**

Director  
Global Regulatory Policy  
MSD

---

5.45 pm **Day End**

---

Session 4 –From Development to Commercialisation

Chair: **Jack Wong**

Founder  
Head of Regulatory Affairs International (RegASK)  
ARPA (Asia Regulatory Professionals Association)

This session will bring together regulatory leaders and experts in the product development field, who will share their experiences and insights on how to increase the chances of commercial success through identifying and reducing the potential barriers.

---

9.00am

**Introduction and overview**

---

Moderator

**Jack Wong**

Founder  
Head of Regulatory Affairs International (RegASK)  
ARPA (Asia Regulatory Professionals Association)

Panel

Regulatory Strategy Planning

**Shun JIN**

Head, Regulatory Affairs, APMA  
Sandoz

Project Management

**Lisa Palladino Kim**

Director of Capstone / Lecturer,  
MS Clinical Research Management,  
Rutgers Biopharma Educational Initiative  
School of Health Professions

Stakeholder Engagement

**Hideyuki Kondo**

Japan Program Head Neuroscience  
& Ophthalmology Development Unit  
Novartis Pharma K.K., Tokyo, Japan

**Mark Chong**

Curriculum co-head  
Singapore Biodesign  
Senior Lecturer  
Nanyang Technological University

**Yasha Huang**

Regulatory Affairs & Policy  
Roche Diagnostics Asia Pacific

---

10.30am

Break

---

Session 5: Fostering an environment for Collaboration among stakeholders

Chair: **Audrey Ooi**

Acting Head - Business Development  
Clinical Research Malaysia

The ongoing healthcare transformation requires multi-stakeholder collaboration to fully harness the value of this exciting evolution. This session will bring collaboration perspectives from patients, innovators and HTA/payers, and will discuss how to foster an environment for such collaboration.

11.00am **Inclusivity – The Importance of Patient Perspective**

- Areas of contribution from patients to improve health management
- Modalities of hearing the patient voice for healthcare decision-making
- Global movement in incorporating patient perspectives

**Rajakanth**

Principal Consultant  
Manifeste LLP

11.20am **Nurturing Innovators**

- Landscape for supporting the growth of innovators and development of ideas
- Gaps in understanding the requirements for product commercial success

**Simon Gordon**

Deputy Director, Venture Building  
SGInnovate

11.40am **Opportunities for Collaboration to Impact Health**

- Case studies of valuable multi-stakeholder collaboration in healthcare
- Creating a suitable environment in ASEAN for healthcare collaboration

**Jeffry Mann**

Partner  
Morgan Lewis

**Yap Wai Ming**

Director  
Morgan Lewis Stamford LLC

12.00pm **Panel Discussion**

**Co-Chairs**

**Finny LIU**

APAC Regional Regulatory Policy Lead, PDR  
Roche, Singapore

**Panelists**

**Simon Gordon**

Deputy Director, Venture Building  
SGInnovate

**Rajakanth**

Principal Consultant  
Manifeste LLP

**Jeffry Mann**

Partner  
Morgan Lewis

**Yap Wai Ming**

Director  
Morgan Lewis Stamford LLC

12.30pm Break

12.45pm **Innovation Hub**  **TriNetX**

13.15 **Day End**

Session 6 – DIAMond Session : Addressing the New Challenges

Co-Chairs

**Finny LIU**

APAC Regional Regulatory  
Policy Lead, PDR  
Roche, Singapore

**Thean Soo (TS) Lo**

Regulatory Affairs Management Consultant

This concluding session will provide the sharing from various representatives of ASEAN regulatory authorities on the progress on oncoming initiatives, as well as thoughts on new approaches to optimise regulatory efficiency and effectiveness.

2.00pm **Relating the Medical Device and Pharmaceutical Regulations**

- Interactions between pharmaceuticals and device regulation and impact on patients
- Opportunities to enhance communications between the two frameworks
- Across both industry and regulators

**Miang Tanakasemsub**

Head  
Regulatory Affairs - Asia Pacific & Russia  
Alcon

**Claire Chin**

Area TA Head  
Regulatory Affairs, JAPAC  
AbbVie

2.30pm **Update on ASEAN ACCSQ PPWG Harmonization Efforts**

**Siti Hidayah binti Kasbon**

Senior Principal Assistant Director  
New Drug Product Section - Centre of Product & Cosmetic Evaluation  
NPRA, Malaysia

3.00pm **Update on ASEAN Medical Device Harmonization Efforts**

**Sethurama Rama**

Director  
Medical Devices Branch, Medical Devices Cluster, Health Products Regulation Group  
Health Sciences Authority

3.30pm **Experience on the WHO-ASEAN Joint Assessment Project**

**Samvel Azatyan**

Unit Head (a.i.), Regulation and Safety [REG], Regulation and Prequalification [RPQ]  
World Health Organization (WHO)

4.00pm Break

4.15 pm **DIAMond Session: Panel Discussion : ASEAN Townhall**

“Addressing unmet medical needs - Maximizing the use of limited resources to expedite access of innovative products for ASEAN patients”

- Sharing of existing pathways for expedited access
- Discussion on furthering the utility of regulatory reliance and cooperation for new health products
- Discussion on the implementation of Good Regulatory Management

**Moderator**

**John Lim**

Executive Director, Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School Singapore

**Panelists**

**Agnes Chan**

Director -Therapeutic Products Branch, Medicinal Products Pre-Market Cluster, Health Sciences Authority

**Samvel Azatyan**

Unit Head (a.i.), Regulation and Safety [REG] Regulation and Prequalification [RPQ] World Health Organization

**Sethurama Rama**

Director - Medical Devices Branch, Medical Devices Cluster, Health Products Regulation Group, Health Sciences Authority

**Siti Hidayah binti Kasbon**

Senior Principal Assistant, Director New Drug Product Section Centre of Product & Cosmetic Evaluation, NPRA, Malaysia

**Jesusa Joyce N. CIRUNAY**

Director IV, Center for Drug Regulation and Research, Food and Drug Administration Philippines

**Thean Soo (TS) Lo**

Regulatory Affairs Management Consultant

**Adelheid Schneider**

Head of Quality and Regulatory Asia Pacific  
Roche Diagnostics Asia Pacific Pte Ltd

5.15 pm **Networking and closing**



# VIRTUAL MEETING

DIA Singapore Annual Meeting 2020 - Driving Healthcare Innovation and Collaboration in Asia (Organised by DIA and CoRE)  
Event I.D. 83320 | 6-7 July & 13-14 July, 2020 | Singapore

## MEETING MANAGER

### Kanchan PATEL

Associate Director Operations  
DIA (India) Private Limited | cell: +91 90.2909.8844 |  
kanchan.patel@diaglobal.org

### Sherna WADIA

Associate Director  
Centre of Regulatory Excellence | Phone: +65 66015147 |  
CoRE@duke-nus.edu.sg

## CANCELLATION POLICY: ON OR BEFORE JUNE 5, 2020

- Cancellations must be in writing and received on or before June 5, 2020. Registrants who do not cancel in writing by that date and do not attend the event will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations.
- DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.
- UPON CANCELLATION, the administrative fee that will be withheld from refund amount is 25 % of the delegate fee

## FULL MEETING CANCELLATION

- Post 5 June 2020 the full registration fee will be forfeited and no refunds will be made.  
All refunds will be issued in the currency of the original payment

## REGISTRATION FEES FOR TWO DAYS CONFERENCE

(Registration fee includes refreshment breaks and luncheons.)

### Early Bird (Until 30th January 2020) (Subject to Payment Realization)

(Exchange rate: 1 USD = 1.36 SGD)

Member	Industry	Registration Fee (SGD)
	Early-bird	900
	Standard	1,100
	On-site	1,300
Academia, Non-Profit	Early-bird	400
	Standard	500
	On-site	600
Non-Member	Early-bird	1,100
	Standard	1,300
	On-site	1,500
Academia, Non-Profit	Early-bird	600
	Standard	700
	On-site	800
Government	Early-bird	400
	Standard	500
Student		200
Membership		w/o tax
DIA Membership		200
2-Year Membership		360
<b>Table Top/Booths</b>		<b>w/o tax</b>
Early Bird		4,000
Standard		5,000

**Sponsorship** Contact: **Kanchan Patel**  
Kanchan.Patel@DIAGlobal.org

**Group Discount** A group of 3-4, 15%/PAX  
A group of 5 and more, 20%/PAX  
Contact: **Kanchan Patel**  
Kanchan.Patel@DIAGlobal.org

For more details, please visit [www.DIAGlobal.org](http://www.DIAGlobal.org)

## DIA MEMBERSHIP

Join DIA now to qualify to save on future events and to receive all the benefits of membership. Visit [www.diahome.org](http://www.diahome.org) and click on Membership for more details

## STUDENT REGISTRATIONS

A student is an undergraduate/graduate who can document enrollment in a signature accredited, degree granting, academic program. Please send completed registration form, payment and copy of student identification.

## DRUG INFORMATION ASSOCIATION

800 Enterprise Road, Suite 200  
Horsham, PA 19044-3595  
tel: 1.215.442.6100 | email: [Americas@diaglobal.org](mailto:Americas@diaglobal.org)

## PAYMENT DETAILS

Wire Transfer Instructions for Drug Information Association INC (USD):

TD Bank NA  
929 Horsham Road,  
Horsham, PA 19044  
ABA#036001808  
ACCOUNT #4271370995  
SWIFT CODE: TDOMCATTOR

Please check the applicable category:

Industry  Government  Academia  Student

PLEASE PRINT ALL INFORMATION CLEARLY

Last Name	First Name	M.I.	Please check one: <input type="checkbox"/> Mr. <input type="checkbox"/> Ms. <input type="checkbox"/> Prof. <input type="checkbox"/> Dr.
Job Position	Affiliation (Company)	<input type="checkbox"/> Business Address <input type="checkbox"/> Home Address	
Address (Please write your address in the format required for delivery to your country.)		City	Postal Country/Region
Address			
Telephone Number	Fax Number	Mobile Number (Required)	Email (Required for confirmation)

IF FAXING OR MAILING THIS FORM, PLEASE PROVIDE A COPY OF REGISTRANT'S BUSINESS CARD.